Biogen stock slips as 2024 outlook disappoints (NASDAQ:BIIB) – InfowayTechnologies

mohd izzuan

Biogen (NASDAQ:BIIB) traded lower in the premarket Tuesday after the company disappointed investors with its Q4 2023 financials and indicated declining revenue this year, amid a flat topline contribution from its new Alzheimer’s therapy, Leqembi.

Cambridge, Massachusetts-based Biogen (BIIB) projected $15.00–$16.00

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button